Encephalitis Treatment Market
Market Insights on Encephalitis Treatment covering sales outlook, demand forecast & up-to-date key trends
Encephalitis Treatment Market by Treatment, End-Users & Region | Forecast 2023 to 2033
Encephalitis Treatment Market Snapshot (2023 to 2033)
The global encephalitis treatment market is currently valued at US$ 20.14 Billion in 2023 and is anticipated to expand at a CAGR of 5.4%. Owing to the technological advances in healthcare the market is likely to propel to US$ 34.08 Billion by 2033.
The increasing prevalence of encephalitis and increasing favorable initiatives to combat the disease with appropriate diagnosis and treatment options are expected to boost market growth during the forecast period.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 20.14 Billion |
|
Projected Forecast Value (2033) |
US$ 34.08 Billion |
|
Global Growth Rate (2023 to 2033) |
5.4% CAGR |
Encephalitis is an infection or an inflammatory response that causes inflammation of the active tissues of the brain. The encephalitis treatment's purpose is to minimize head swelling and avoid unwanted problems.
If encephalitis is caused by a bacterial infection, intravenous antibiotics can be used to treat it. Supportive treatment, as well as intravenous antiviral medication with acyclovir, are used to treat herpes-related encephalitis. Other therapies include lowering the fever, hydrating the patient, treating seizures if they occur, and reducing any pressure in the skull.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which are Some Prominent Drivers of the Encephalitis Treatment Market?
Growing Incidences of Encephalitis to Drive the Market Growth
The major factor attributing to the growth of the market is the high mortality and morbidity rate caused due to the incidence of encephalitis virus. Furthermore, increasing government initiatives for vaccination programs is boosting the market. For instance, according to the World Health Organization as of April 28, 2022, 37 human cases of Japanese encephalitis (25 laboratory-confirmed cases and 12 probable cases) had been documented in four Australian states.
As the number of cases and fatalities rises, individuals must take preventive measures such as immunization, which increases demand for encephalitis treatment, thereby boosting market growth.
The rise in the incidences of cancer will act as a major driver that will result in the expansion of the growth rate of the market. When the body is fighting cancer, certain immune system illnesses might induce encephalitis which will increase the occurrence rate of encephalitis.
Growing Investment for Healthcare Infrastructure to Boost the Market Growth During Forecast Period.
Another significant factor influencing the growth rate of the encephalitis treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, the increase in the popularity of physical therapy across the globe will enhance the growth of the encephalitis treatment market. Furthermore, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the encephalitis treatment market.
Other factors such as an increase in the demand for effective therapies and rising spending on public health programs will positively impact the encephalitis treatment market's growth rate.
Additionally, high disposable income, a rising geriatric population, and changing lifestyles will result in the expansion of the encephalitis treatment market. Increasing research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.
For instance, in August 2021, Pfizer received United States Food and Drug Administration (USFDA) approval for Tick-Borne Encephalitis (TBE) Vaccine named TICOVAC. It can produce neutralizing antibodies against the TBE virus in the wild. TICOVAC contains albumin, a human blood product. It carries a very low risk of transmission of viral illness and variant Creutzfeldt-Jakob disease (vCJD) transmission because of efficient donor screening and product production processes.
Which factors are limiting the growth of the Encephalitis Treatment Market?
Lack of Skilled Professionals May Hamper the Market Growth
Although the encephalitis treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth.
The high cost associated with the treatment and the lack of infrastructure in low-income countries will impede the growth rate of the encephalitis treatment market. Additionally, the dearth of skilled professionals will hinder the encephalitis treatment market growth. Less awareness among patients will further challenge the market in the forecast period mentioned above.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystCountry-Wise Insights
What Makes USA an Attractive Market for Encephalitis Treatment?
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 5.2% during the forecast period.
The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American encephalitis treatment market in the years to come.
Encephalitis affects 10-15 persons per 100,000 each year, with over 250,000 cases diagnosed in the USA in the last decade. The illness can affect anyone, but it is more common in children and teenagers. The HIV-infected population accounts for about 15% of encephalitis cases.
Incidence of encephalitis in children in the US has increased over the past 10 years which may be partially attributed to the increasing use of immunosuppressive therapies and bone marrow and solid organ transplantation associated with an increased risk of encephalitis, as well as improved sensitivity of brain parenchymal imaging using magnetic resonance imaging (MRI).
Why Is Europe Emerging as an Opportunistic Encephalitis Treatment Market?
Increasing Investment in Healthcare Infrastructure Provides an Opportunity for Market Growth
Europe is expected to have the second maximum market share of the encephalitis treatment market due to the high number of people suffering from COPD and asthma in the region.
In addition, the high adoption rate of advanced diagnostic devices, easy obtainability of diagnostic test kits, increasing awareness about early diagnosis, and increased number of diagnostic centers are also expected to fuel region expansion during the forecast period. Moreover, various government initiatives to promote the diagnosis of various infectious diseases are likely to offer lucrative growth opportunities during the coming year.
What makes the Asia Pacific the Most Lucrative Market for Encephalitis Treatment Market?
Increasing Prevalence of Japanese Encephalitis in the Region to Boost the Market Growth
The Asia Pacific encephalitis treatment market is expected to rise at a CAGR of 5.1% from 2023 to 2033. Asia Pacific dominates the encephalitis treatment market owing to the high geriatric population and increasing disease burden in economies such as India, China, and South Korea.
According to the updates from European Centre for Disease Prevention and Control in March 2022, the Japanese Encephalitis virus can be found throughout Asia and Oceania, from Japan to India, Pakistan, and Australia.
The growing healthcare industry and an aging population consequently would lead to an increased patient population in these countries. India, China, and Brazil are expected to be rapidly growing markets, owing to an increase in investments by governments in order to enhance healthcare facilities.
Growing investment in the Research and Development sector, entry of new vaccine manufacturers in countries like India and China, an increasing number of travelers in the region, and medical tourism is propelling the market growth in the region.
Country-wise Forecast CAGRs for Encephalitis Treatment Market
|
United Kingdom |
5.1% |
|
India |
5.1% |
|
South Korea |
5.0% |
|
China |
4.8% |
|
United States of America |
5.2% |
Category wise Insights
By End-Users, Which Segment Generates High Revenue in The Encephalitis Treatment Market?
Hospital Segment Remains Dominant Among Other Types
The hospital segment held the largest market share of 50.5% in 2023 owing to the wide adoption of advanced technology in hospital settings. The availability of various treatment options in such facilities increases the number of visits for encephalitis diagnosis and treatments, which, in turn, supports segment growth.
The clinic's end-user segment is estimated to register the fastest CAGR from 2023 to 2033. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Start-up Scenario
How do New Entrants Contribute to the Encephalitis Treatment Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the encephalitis treatment market.
Some of the start-ups in the encephalitis treatment market include-
- SingVax was focused on the development of prophylactic vaccines for infectious diseases. The company’s product candidates include the Enterovirus 71 vaccine for the prevention of hand, foot, and mouth disease in children; the Japanese Encephalitis (JE) vaccine for the prevention of JE virus infection; and the chikungunya virus vaccine. As of Oct 2009, SingVax was acquired by Invitrogen.
- Inviragen was developing vaccines to protect against infectious diseases, including dengue, hand, foot, and mouth disease, chikungunya, Japanese encephalitis, influenza, and a combination plague/smallpox vaccine for biodefense. It was acquired by Takeda in 2013 for an upfront payment of $35 M, and future payments of up to $215 M linked to the progress of l development and achievement of key commercial milestones.
- Rhein Biotech - Developer of therapeutic solutions for the treatment of infectious & inflammatory diseases. The company has developed a HEPLISAV lead candidate that helps in treating hepatitis B. It also provides vaccines and immune modulators that help in the treatment of multiple diseases like diphtheria, encephalitis, typhoid, tetanus, hemorrhagic fever, and influenza.
Competitive Landscape
Some of the key players present in the global encephalitis treatment markets are Allergan, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Abbott, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
- In December 2022, The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE). In May 2022, Dupixent 300 mg weekly was approved by the USA Food and Drug Administration for the treatment of patients aged 12 years and older, weighing at least 40 kg.
- In February 2021, Pfizer Inc. announced that the USA Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older.1,2
- In January 2023, Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that the continued strong sales of the antifungal Cresemba® (isavuconazole) achieved by its partner Astellas Pharma Inc. (Astellas) in the USA in 2022.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR 5.4% from 2023 to 2033 |
|
Expected Market Value (2023) |
US$ 20.14 Billion |
|
Projected Forecast Value (2033) |
US$ 34.08 Billion |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Billion & CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Covered in the Encephalitis Treatment Industry Survey
Encephalitis Treatment Market by Treatment:
- Antiviral Agents
- Steroid Injection
- Antibiotics
- Immunoglobulin Therapy
- Plasmapheresis
- Others
Encephalitis Treatment Market by End-Users:
- Clinic
- Hospitals
- Others
Encephalitis Treatment Market by Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
What is the expected valuation of the encephalitis treatment market?
The global encephalitis treatment market is likely to reach a valuation of US$ 20.14 billion by the end of 2023.
Who are the key players in the encephalitis treatment market?
Allergan, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., are some of the key players in the global encephalitis treatment market.
What are the future prospects of encephalitis treatment market sales?
Sales of the encephalitis treatment market are likely to expand at 5.4% CAGR through 2033.
Which are the top 5 countries driving demand for encephalitis treatment?
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the encephalitis treatment market.
What will be the global encephalitis treatment market revenue total by 2033?
By the end of 2033, the global market for encephalitis treatment market is predicted to reach a valuation of US$ 34.08 Billion.
Table of Content
1. Executive Summary | Encephalitis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Antiviral Agents 5.3.2. Steroid Injection 5.3.3. Antibiotics 5.3.4. Immunoglobulin Therapy 5.3.5. Plasmapheresis 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End-Users, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users, 2023 to 2033 6.3.1. Clinic 6.3.2. Hospital 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa (MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. US 8.2.1.2. Canada 8.2.2. By Treatment 8.2.3. By End-Users 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.3.3. By End-Users 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment 9.2.3. By End-Users 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By End-Users 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment 10.2.3. By End-Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By End-Users 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Singapore 11.2.1.5. Thailand 11.2.1.6. Indonesia 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of Asia Pacific 11.2.2. By Treatment 11.2.3. By End-Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By End-Users 11.4. Key Takeaways 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of MEA 12.2.2. By Treatment 12.2.3. By End-Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By End-Users 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. US 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2022 13.1.2.1. By Treatment 13.1.2.2. By End-Users 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2022 13.2.2.1. By Treatment 13.2.2.2. By End-Users 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2022 13.3.2.1. By Treatment 13.3.2.2. By End-Users 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2022 13.4.2.1. By Treatment 13.4.2.2. By End-Users 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2022 13.5.2.1. By Treatment 13.5.2.2. By End-Users 13.6. United Kingdom 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2022 13.6.2.1. By Treatment 13.6.2.2. By End-Users 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2022 13.7.2.1. By Treatment 13.7.2.2. By End-Users 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2022 13.8.2.1. By Treatment 13.8.2.2. By End-Users 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2022 13.9.2.1. By Treatment 13.9.2.2. By End-Users 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2022 13.10.2.1. By Treatment 13.10.2.2. By End-Users 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2022 13.11.2.1. By Treatment 13.11.2.2. By End-Users 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2022 13.12.2.1. By Treatment 13.12.2.2. By End-Users 13.13. Singapore 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2022 13.13.2.1. By Treatment 13.13.2.2. By End-Users 13.14. Thailand 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2022 13.14.2.1. By Treatment 13.14.2.2. By End-Users 13.15. Indonesia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2022 13.15.2.1. By Treatment 13.15.2.2. By End-Users 13.16. Australia 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2022 13.16.2.1. By Treatment 13.16.2.2. By End-Users 13.17. New Zealand 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2022 13.17.2.1. By Treatment 13.17.2.2. By End-Users 13.18. GCC Countries 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2022 13.18.2.1. By Treatment 13.18.2.2. By End-Users 13.19. South Africa 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2022 13.19.2.1. By Treatment 13.19.2.2. By End-Users 13.20. Israel 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2022 13.20.2.1. By Treatment 13.20.2.2. By End-Users 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Treatment 14.3.3. By End-Users 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Allergan 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Merck & Co., Inc. 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Pfizer Inc. 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. GlaxoSmithKline plc 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Melinta Therapeutics LLC 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Basilea Pharmaceutica Ltd. 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Abbott 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. F. Hoffmann-La Roche Ltd. 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Teva Pharmaceutical Industries Ltd. 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Sanofi 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by End-Users, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by End-Users, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by End-Users, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by End-Users, 2018 to 2033 Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: Asia Pacific Market Value (US$ Million) Forecast by End-Users, 2018 to 2033 Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 18: MEA Market Value (US$ Million) Forecast by End-Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by End-Users, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by End-Users, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033 Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 14: Global Market Attractiveness by End-Users, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by End-Users, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by End-Users, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033 Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 29: North America Market Attractiveness by End-Users, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by End-Users, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by End-Users, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 44: Latin America Market Attractiveness by End-Users, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by End-Users, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by End-Users, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033 Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 59: Europe Market Attractiveness by End-Users, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: Asia Pacific Market Value (US$ Million) by End-Users, 2023 to 2033 Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End-Users, 2018 to 2033 Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033 Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033 Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033 Figure 74: Asia Pacific Market Attractiveness by End-Users, 2023 to 2033 Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 77: MEA Market Value (US$ Million) by End-Users, 2023 to 2033 Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 85: MEA Market Value (US$ Million) Analysis by End-Users, 2018 to 2033 Figure 86: MEA Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033 Figure 87: MEA Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033 Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 89: MEA Market Attractiveness by End-Users, 2023 to 2033 Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
